8:01AM Quidel and Life Technologies (LIFE) receive FDA clearance for Clostridium difficile Assay and Quantstudio DX and 7500 Fast DX Real-Time PCR Instruments (QDEL) 23.92 : Quidel (QDEL) and Life Technologies (LIFE) announces that they received 510(k) clearances from the FDA to market the Quidel Molecular Direct C. difficile Assay with Life Technologies' QuantStudio Dx and 7500 Fast Dx Applied Biosystems Real-Time PCR Instruments. Clostridium difficile bacterial infections are life-threatening, especially for the elderly, immunocompromised populations, and for patients on a prolonged antibiotic regimen.
Recent QDEL News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 05:03:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:12:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:10:52 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:06:23 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:07:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:07:20 PM
- Understanding and Addressing Syphilis Trends - and What's Being Missed • PR Newswire (US) • 04/23/2026 01:32:00 PM
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics • PR Newswire (US) • 04/20/2026 11:12:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:15:43 PM
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance • PR Newswire (US) • 04/15/2026 08:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:40:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 11:00:12 AM
- Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer • PR Newswire (US) • 03/24/2026 11:00:00 AM
- Faster Cardiac Answers with High‑Sensitivity Troponin • PR Newswire (US) • 02/19/2026 02:17:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/19/2026 02:45:21 AM
- QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference • PR Newswire (US) • 02/18/2026 09:05:00 PM
- QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio • PR Newswire (US) • 02/16/2026 06:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 09:21:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:07:04 PM
- QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 02/11/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 09:19:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:51:39 AM

